Correlation Between Caribou Biosciences and Entrada Therapeutics

Can any of the company-specific risk be diversified away by investing in both Caribou Biosciences and Entrada Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Caribou Biosciences and Entrada Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Caribou Biosciences and Entrada Therapeutics, you can compare the effects of market volatilities on Caribou Biosciences and Entrada Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Caribou Biosciences with a short position of Entrada Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Caribou Biosciences and Entrada Therapeutics.

Diversification Opportunities for Caribou Biosciences and Entrada Therapeutics

0.56

Correlation Coefficient

Caribou Biosciences  Entrada Therapeutics

Very weak diversification

The 3 months correlation between Caribou and Entrada is 0.56. Overlapping area represents the amount of risk that can be diversified away by holding Caribou Biosciences and Entrada Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Entrada Therapeutics and Caribou Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Caribou Biosciences are associated (or correlated) with Entrada Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Entrada Therapeutics has no effect on the direction of Caribou Biosciences i.e., Caribou Biosciences and Entrada Therapeutics go up and down completely randomly.

Pair Corralation between Caribou Biosciences and Entrada Therapeutics

Given the investment horizon of 90 days Caribou Biosciences is expected to under-perform the Entrada Therapeutics. In addition to that, Caribou Biosciences is 1.27 times more volatile than Entrada Therapeutics. It trades about -0.28 of its total potential returns per unit of risk. Entrada Therapeutics is currently generating about -0.17 per unit of volatility. If you would invest  1,989  in Entrada Therapeutics on September 29, 2024 and sell it today you would lose (248.00) from holding Entrada Therapeutics or give up 12.47% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Caribou Biosciences  vs.  Entrada Therapeutics

Caribou Biosciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Caribou Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's fundamental drivers remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Entrada Therapeutics

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Entrada Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady fundamental indicators, Entrada Therapeutics may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Caribou Biosciences and Entrada Therapeutics

The main advantage of trading using opposite Caribou Biosciences and Entrada Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Caribou Biosciences position performs unexpectedly, Entrada Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entrada Therapeutics will offset losses from the drop in Entrada Therapeutics' long position.

The idea behind Caribou Biosciences and Entrada Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.